miR-15/16 deletion leads to the overexpression of several target genes depending on the specific tissue, including the anti-apoptotic factor B cell lymphoma 2 (BCL2) in CLL [56]; the cyclooxygenase-2 (COX-2) gene in colon cancer [57]; cyclin D1, the proto-oncogene protein WNT3, in prostate cancer [58]; VEGFa in multiple myeloma; and genes, such as C-MYC and ALK in other tumors [59,60]. The gene discussed is PTGS2; the disease is plasma cell myeloma.